GlassScriptPhysician profile
Floye Taylor
NPI 1023211521
$2,240.38
in general payments reported to CMS, 2019-2025
19 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2022: $555 · 2023: $649 · 2024: $633 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.08 |
| Education | $124.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $533.23 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $428.54 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $305.89 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.76 | 2021-2023 | Synjardy, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.47 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $120.26 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $86.86 | 2021-2025 | Zepbound |
| Abbott Laboratories | $76.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.98 | 2021-2023 | Trulance, Xifaxan |
| Novo Nordisk INC | $51.77 | 2023-2024 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $49.71 | 2023-2024 | Xyosted, Tlando, Qelbree |
| Janssen Pharmaceuticals, INC | $44.97 | 2022 | |
| Pfizer INC. | $38.13 | 2021-2025 | |
| Halozyme INC | $37.26 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $31.39 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.10 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.79 | 2024 | Quviviq |
| Acella Pharmaceuticals, LLC | $15.40 | 2024 | NP Thyroid 60 |
| Phathom Pharmaceuticals, INC. | $13.40 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floye Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.